CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-15 | Greenwood Luba Director | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2023-06-15 | Graff Jeremy R. Director | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2023-06-15 | Roemer Alan S. Director | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2023-05-01 | Graff Jeremy R. Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-04-14 | Ho William Tai-Wei President and CEO | Grant or award · Employee Stock Option (right to buy) | +393,950 | 393,950 | ||
| 2023-04-14 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2023-04-14 | McCall Patrick Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2023-04-14 | Lamb Lawrence EVP and CSO | Grant or award · Employee Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2023-04-14 | Ho William Tai-Wei President and CEO | Grant or award · Employee Stock Option (right to buy) | +393,950 | 393,950 | ||
| 2023-04-14 | Goswami Trishna Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2022-12-12 | Kreis Leslie W. Director | Purchase | +9,214 | $2.48 | $23K | 601,980 |
| 2022-12-12 | Kreis Leslie W. Director | Purchase | +57,052 | $2.48 | $141K | 3,727,597 |
| 2022-12-12 | Kreis Leslie W. Director | Purchase | +8,735 | $2.48 | $22K | 570,724 |
| 2022-12-12 | Fletcher Aaron G.L. Director | Purchase | +9,214 | $2.48 | $23K | 601,980 |
| 2022-12-12 | Fletcher Aaron G.L. Director | Purchase | +57,052 | $2.48 | $141K | 3,727,597 |
| 2022-12-12 | Fletcher Aaron G.L. Director | Purchase | +8,735 | $2.48 | $22K | 570,724 |
| 2022-10-21 | McCall Patrick Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +59,796 | 59,796 | ||
| 2022-10-21 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +60,555 | 60,555 | ||
| 2022-10-21 | Lamb Lawrence EVP and CSO | Grant or award · Employee Stock Option (right to buy) | +62,826 | 62,826 | ||
| 2022-10-21 | Ho William Tai-Wei President, CEO and CFO | Grant or award · Employee Stock Option (right to buy) | +83,265 | 83,265 |
Page 10 of 16 · 309 trades